Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Phase
3.2. Snippet by Study Design
3.3. Snippet by Therapeutic Areas
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Pediatric Diseases and Technological Advancements
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. High Cost of Clinical Studies
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. By Phase
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase
6.1.2. Market Attractiveness Index, By Phase
6.2. Phase I *
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Phase II
6.4. Phase III
6.5. Phase IV
7. By Study Design
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Design
7.1.2. Market Attractiveness Index, By Study Design
7.2. Treatment Studies*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Observational Studies
7.3.1. Prospective Cohort
7.3.2. Case-Control Study
7.3.3. Cohort Study
7.3.4. Cross-Sectional Study
7.3.5. Ecological Study
8. By Therapeutic Areas
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Areas
8.1.2. Market Attractiveness Index, By Therapeutic Areas
8.2. Oncology *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Autoimmune or Inflammatory Diseases
8.4. Respiratory Diseases
8.5. Infectious Diseases
8.6. Mental Health Disorders
8.7. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Design
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Areas
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Design
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Areas
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Design
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Areas
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Design
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Areas
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Design
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Areas
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Pfizer Inc*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. ICON plc
11.3. GSK plc
11.4. Syneos Health
11.5. Bristol-Myers Squibb Company
11.6. IQVIA Inc.
11.7. Thermo Fisher Scientific Inc. (PPD Inc.)
11.8. Novartis AG
11.9. The Emmes Company, LLC
11.10. Medpace (*LIST NOT EXHAUSTIVE)
12. Appendix
12.1. About Us and Services
12.2. Contact Us